Hemofiltration as a treatment for end‐stage renal disease

Zimmerman, Deborah

doi:10.1111/j.1492-7535.2004.01093.x

Cited by 4 publications

(5 citation statements)

References 35 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lower predialysis serum b2-microglobulin has been reported with quotidian hemodiafiltration [3 ]. Early clinical results from the use of the short daily hemofiltration are encouraging [4 ].…”

Section: Daily Hemofiltrationmentioning

confidence: 99%

Quotidian dialysis – update 2005

Pierratos¹,

McFarlane²,

Chan³

2005

Current Opinion in Nephrology and Hypertension

View full text Add to dashboard Cite

There is increasing evidence confirming that quotidian hemodialysis improves clinical outcomes in a cost-efficient manner. Provided that the reimbursement issues are resolved these modalities may be utilized extensively at home as well as in the in-center facilities. The revitalization of home hemodialysis will compensate for the decline in utilization of continuous ambulatory peritoneal dialysis and the nursing shortage encountered in most countries.

show abstract

Section: Daily Hemofiltrationmentioning

confidence: 99%

Quotidian dialysis – update 2005

Pierratos¹,

McFarlane²,

Chan³

2005

Current Opinion in Nephrology and Hypertension

View full text Add to dashboard Cite

show abstract

“…Increasing the frequency and/or duration of dialysis utilizing diffusive dialytic techniques and user‐friendly delivery machines has been advocated by some 3–9 . Others have developed convective forms of therapy utilizing high‐efficiency and high‐flux dialyzers in a variety of configurations, some combined with diffusive solute removal as well 10,11 …”

Section: Laboratory Results: Molecularly Engineered Passage Of Cationmentioning

confidence: 99%

“…[3][4][5][6][7][8][9] Others have developed convective forms of therapy utilizing high-efficiency and high-flux dialyzers in a variety of configurations, some combined with diffusive solute removal as well. 10,11 Modality selection remains driven primarily by reimbursement throughout the world, 12,13 however, in part because a compelling clinical case for one modality over another has not been made. The advances in the technical delivery of dialysis that have been seen in the past decade have resulted in better patient tolerance to therapy, but have had little impact on primary outcomes such as mortality.…”

mentioning

confidence: 99%

Continuously functioning artificial nephron system: The promise of nanotechnology

Nissenson

Ronco

Pergamit

et al. 2005

Hemodialysis International

View full text Add to dashboard Cite

Nearly 900,000 patients worldwide have end-stage renal disease and require dialysis or kidney transplantation. Despite the availability of these forms of renal replacement therapy for nearly four decades, mortality and morbidity are high and patients often have a poor quality of life. We have developed a human nephron filter (HNF) utilizing nanotechnology that would eventually make feasible a continuously functioning, wearable or implantable artificial kidney. The device consists of two membranes operating in series within one device cartridge. The first membrane mimics the function of the glomerulus, using convective transport to generate a plasma ultrafiltrate containing all solutes approaching the molecular weight of albumin. The second membrane mimics the function of the renal tubules, selectively reclaiming designated solutes to maintain body homeostasis. No dialysis solution is used in this device. The HNF has been computer-modeled, and operating 12 hr per day, 7 days per week the HNF provides the equivalent of 30 mL/min glomerular filtration rate (compared to half that amount for conventional thrice-weekly hemodialysis). Animal studies should begin in the next 1 to 2 years, and clinical trials would then follow 1 to 2 years subsequent. The HNF system, by eliminating dialysate and utilizing a novel membrane system created through applied nanotechnology, represents a breakthrough in renal replacement therapy based on the functioning of native kidneys. The enhanced solute removal and wearable design should substantially improve patient outcomes and quality of life.

show abstract

“…Increasing the frequency and ⁄ or duration of dialysis utilizing diffusive dialytic techniques and user-friendly delivery machines has been advocated by some (3)(4)(5)(6)(7)(8)(9). Others have developed convective forms of therapy utilizing high-efficiency and high-flux dialyzers in a variety of configurations, some combined with diffusive solute removal as well (10,11).…”

mentioning

confidence: 99%

Innovation in the Treatment of Uremia: Proceedings from the Cleveland Clinic Workshop: Bottom‐Up Nanotechnology: The Human Nephron Filter

Nissenson¹

2009

Seminars in Dialysis

View full text Add to dashboard Cite

Over one million patients worldwide have end-stage renal disease and require dialysis or kidney transplantation. Despite the availability of these forms of renal replacement therapy for nearly four decades, mortality and morbidity are high and patients often have a poor quality of life. We have developed a human nephron filter (HNF) utilizing bottom-up nanotechnology that would eventually make feasible a continuously functioning, wearable or implantable artificial kidney. The device consists of two membranes operating in series within one device cartridge. The first membrane mimics the function of the glomerulus, using convective transport to generate a plasma ultra filtrate, which contains all solutes approaching the molecular weight of albumin. The second membrane mimics the function of the renal tubules, selectively reclaiming designated solutes to maintain body homeostasis. No dialysis solution is used in this device. The HNF has been computer modeled, and operating 12 hour per day, 7 days per week the HNF provides the equivalent of 30 ml/min glomerular filtration rate (compared to half that amount for conventional thrice-weekly hemodialysis). The HNF system, by eliminating dialysate and utilizing a novel membrane system created through applied nanotechnology, represents a breakthrough in renal replacement therapy based on the functioning of native kidneys. The enhanced solute removal and wearable design should substantially improve patient outcomes and quality of life.

show abstract

Hemofiltration as a treatment for end‐stage renal disease

Cited by 4 publications

References 35 publications

Quotidian dialysis – update 2005

Quotidian dialysis – update 2005

Continuously functioning artificial nephron system: The promise of nanotechnology

Innovation in the Treatment of Uremia: Proceedings from the Cleveland Clinic Workshop: Bottom‐Up Nanotechnology: The Human Nephron Filter

Contact Info

Product

Resources

About